NASDAQ:FBRX Forte Biosciences (FBRX) Stock Price, News & Analysis $0.56 -0.01 (-1.76%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.55▼$0.5850-Day Range$0.48▼$0.6552-Week Range$0.38▼$1.03Volume9,810 shsAverage Volume26,790 shsMarket Capitalization$20.30 millionP/E RatioN/ADividend YieldN/APrice Target$3.38 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Forte Biosciences alerts: Email Address Forte Biosciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside505.8% Upside$3.38 Price TargetShort InterestHealthy0.03% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.88Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.59) to ($0.55) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.71 out of 5 starsMedical Sector258th out of 936 stocksPharmaceutical Preparations Industry116th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingForte Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageForte Biosciences has only been the subject of 1 research reports in the past 90 days.Read more about Forte Biosciences' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.03% of the outstanding shares of Forte Biosciences have been sold short.Short Interest Ratio / Days to CoverForte Biosciences has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Forte Biosciences has recently decreased by 41.87%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldForte Biosciences does not currently pay a dividend.Dividend GrowthForte Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for FBRX. Previous Next 2.7 News and Social Media Coverage News SentimentForte Biosciences has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Forte Biosciences this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for FBRX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Forte Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders10.53% of the stock of Forte Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions77.63% of the stock of Forte Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Forte Biosciences' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Forte Biosciences are expected to grow in the coming year, from ($0.59) to ($0.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Forte Biosciences is -0.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Forte Biosciences is -0.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioForte Biosciences has a P/B Ratio of 0.57. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Forte Biosciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad MarketBeatWe just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.Start Your Risk-Free Trial Here About Forte Biosciences Stock (NASDAQ:FBRX)Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.Read More FBRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FBRX Stock News HeadlinesJuly 25 at 2:10 AM | americanbankingnews.comStock Traders Buy High Volume of Call Options on Forte Biosciences (NASDAQ:FBRX)July 15, 2024 | insidermonkey.comIs Forte Biosciences, Inc. (FBRX) One of the Best Penny Stocks to Buy Now Under $1?July 26, 2024 | MarketBeat (Ad)We just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.May 21, 2024 | finance.yahoo.comCompanies Like Forte Biosciences (NASDAQ:FBRX) Could Be Quite RiskyMay 17, 2024 | businesswire.comForte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing RulesMay 13, 2024 | investorplace.comFBRX Stock Earnings: Forte Biosciences Reported Results for Q1 2024May 13, 2024 | businesswire.comForte Biosciences, Inc. Announces First Quarter 2024 Results and Provides Business UpdateApril 10, 2024 | benzinga.comForte Biosciences Stock (NASDAQ:FBRX), Analyst Ratings, Price Targets, PredictionsJuly 26, 2024 | MarketBeat (Ad)We just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.April 8, 2024 | markets.businessinsider.comBuy Recommendation for Forte Biosciences on Strong Potential of Novel FB-102 Treatment and Market PositionMarch 19, 2024 | investorplace.comFBRX Stock Earnings: Forte Biosciences Reported Results for Q4 2023March 18, 2024 | businesswire.comForte Biosciences, Inc. Announces 2023 Results and Provides Business UpdateDecember 12, 2023 | morningstar.comForte Biosciences Inc Ordinary SharesDecember 9, 2023 | finance.yahoo.comWe Think Forte Biosciences (NASDAQ:FBRX) Needs To Drive Business Growth CarefullyNovember 15, 2023 | morningstar.comForte Biosciences Inc Ordinary Shares FBRXNovember 14, 2023 | msn.comForte Biosciences GAAP EPS of -$0.26November 13, 2023 | finance.yahoo.comForte Biosciences, Inc. Announces Third Quarter 2023 Results and Provides Business UpdateSeptember 14, 2023 | benzinga.comISS and Glass Lewis Recommend Forte Biosciences Stockholders Vote FOR Boardroom Change at the Company's Upcoming Annual MeetingSee More Headlines Receive FBRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Forte Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today7/26/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:FBRX CUSIPN/A CIK1419041 Webwww.fortebiorx.com Phone(310) 618-6994FaxN/AEmployees5Year FoundedN/APrice Target and Rating Average Stock Price Target$3.38 High Stock Price Target$4.00 Low Stock Price Target$2.75 Potential Upside/Downside+505.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-31,480,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-99.44% Return on Assets-85.68% Debt Debt-to-Equity RatioN/A Current Ratio9.45 Quick Ratio9.45 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.97 per share Price / Book0.57Miscellaneous Outstanding Shares36,440,000Free Float32,605,000Market Cap$20.30 million OptionableOptionable Beta0.09 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Paul A. Wagner Ph.D. (Age 54)CEO, President & Chairman Comp: $960.23kMr. Antony A. Riley CPA (Age 57)Chief Financial Officer Comp: $568.48kDr. Barbara K. Finck M.D. (Age 77)Chief Medical Clinician & Director Comp: $45kMr. Christopher RoenfeldtChief Operating OfficerMr. Steven Ruhl (Age 67)Chief Technical Officer Key CompetitorsBeyondSpringNASDAQ:BYSICASI PharmaceuticalsNASDAQ:CASIVerastemNASDAQ:VSTMLifeVantageNASDAQ:LFVNAssembly BiosciencesNASDAQ:ASMBView All CompetitorsInsidersPaul A WagnerBought 10,000 shares on 12/18/2023Total: $7,500.00 ($0.75/share)Paul A WagnerBought 10,520 shares on 12/13/2023Total: $7,364.00 ($0.70/share)Paul A WagnerBought 25,000 shares on 12/11/2023Total: $16,250.00 ($0.65/share)Paul A WagnerBought 36,203 shares on 12/7/2023Total: $20,997.74 ($0.58/share)Paul A WagnerBought 400 shares on 11/22/2023Total: $172.00 ($0.43/share)View All Insider Transactions FBRX Stock Analysis - Frequently Asked Questions How have FBRX shares performed this year? Forte Biosciences' stock was trading at $0.8217 on January 1st, 2024. Since then, FBRX stock has decreased by 32.2% and is now trading at $0.5571. View the best growth stocks for 2024 here. How were Forte Biosciences' earnings last quarter? Forte Biosciences, Inc. (NASDAQ:FBRX) posted its earnings results on Monday, May, 13th. The company reported ($0.16) earnings per share (EPS) for the quarter. How do I buy shares of Forte Biosciences? Shares of FBRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Forte Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Forte Biosciences investors own include Trevena (TRVN), Chimerix (CMRX), electroCore (ECOR), Great Panther Mining (GPL). This page (NASDAQ:FBRX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredWhy is NVDA stumbling?July is historically the best month of the year for U.S. stocks. So why are everyone’s favorite tech stocks...Chaikin Analytics | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Forte Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Forte Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FBRX Stock Alerts